isradipine has been researched along with Diabetes Mellitus, Type 2 in 12 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a prospective randomized study, 14 patients with NIDDM, hypertension, proteinuria, and renal insufficiency were given either isradipine (n = 7) or nifedipine XL (n = 7) for 6 months." | 5.08 | Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. ( Abbott, K; Bakris, GL; Smith, A, 1996) |
| " In the long-term study presented here, the effects of isradipine, a dihydropyridine calcium antagonist, on the course of the nephropathy were investigated and compared with the effects of captopril in 31 African Americans with NIDDM and proteinuria (> or = 500 mg/day)." | 5.08 | Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. ( Campbell, O; Guasch, A; Macon, E; Nzerue, C; Parham, M; Zayas, CF, 1997) |
| " Therefore, the effects of isradipine, a new calcium antagonist, on glucose tolerance and insulin secretion during a 75-g oral glucose tolerance test (OGTT) and on ADP- and collagen-induced maximum first-wave platelet aggregation (Tmax%) were studied in 11 type II diabetic patients with borderline hypertension." | 5.06 | Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. ( Gisinger, C; Klauser, R; Prager, R; Schernthaner, G; Speiser, P, 1990) |
| " With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity." | 3.69 | [Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (91.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christensen, PK | 1 |
| Akram, K | 1 |
| Kønig, KB | 1 |
| Parving, HH | 1 |
| Moiseev, VS | 1 |
| Ivleva, AIa | 1 |
| Kobalava, ZhD | 1 |
| Farsang, C | 1 |
| Kapocsi, J | 1 |
| Kiss, I | 1 |
| Török, E | 1 |
| Kerkovits, G | 1 |
| Holló, J | 1 |
| Jávor, T | 1 |
| Gomis, R | 1 |
| Vidal, J | 1 |
| Novials, A | 1 |
| Coves, MJ | 1 |
| Parreira, JM | 1 |
| Correia, LG | 1 |
| Pereira, E | 1 |
| Duarte, RS | 1 |
| Pape, E | 1 |
| Ferrara, LA | 1 |
| De Simone, G | 1 |
| Iannuzzi, R | 1 |
| Gaeta, I | 1 |
| D'Orta, G | 1 |
| Turco, S | 1 |
| Guida, L | 1 |
| Marotta, T | 1 |
| Abbott, K | 1 |
| Smith, A | 1 |
| Bakris, GL | 1 |
| Ranieri, G | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Bonfantino, MV | 1 |
| Lamontanara, G | 1 |
| Cavallo, A | 1 |
| Milani, M | 1 |
| De Cesaris, R | 1 |
| Touyz, RM | 1 |
| Schiffrin, EL | 1 |
| Guasch, A | 1 |
| Parham, M | 1 |
| Zayas, CF | 1 |
| Campbell, O | 1 |
| Nzerue, C | 1 |
| Macon, E | 1 |
| Klauser, R | 2 |
| Speiser, P | 1 |
| Gisinger, C | 2 |
| Schernthaner, G | 2 |
| Prager, R | 2 |
| Gaube, S | 1 |
| Schnack, C | 1 |
| Küenburg, E | 1 |
11 trials available for isradipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clonidine; Cross-Over Studi | 2003 |
Hungarian Isradipine Study (HIS): long-term (3-year) effects on blood pressure and plasma lipids.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Dru | 1994 |
Effects of isradipine and nifedipine retard in hypertensive patients with type II diabetes mellitus.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female; | 1993 |
Antihypertensive efficacy, safety, and tolerability of isradipine in hypertensive patients with diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy | 1993 |
Metabolic effects of isradipine in non-insulin-dependent diabetes mellitus (NIDDM) hypertensive patients.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Delayed-Act | 1995 |
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes.
Topics: Adult; Albuminuria; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, S | 1996 |
Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.
Topics: Antihypertensive Agents; beta-Thromboglobulin; Blood Pressure; Calcium Channel Blockers; Delayed-Act | 1996 |
Treatment of non-insulin-dependent diabetic hypertensive patients with Ca2+ channel blockers is associated with increased platelet sensitivity to insulin.
Topics: Angiotensin II; Antihypertensive Agents; Blood Platelets; Blood Pressure; Calcium; Calcium Channel B | 1995 |
Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Black People; Calcium Channel Blockers; Capto | 1997 |
Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diet; Double-Bli | 1990 |
Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucos | 1991 |
1 other study available for isradipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin; | 1995 |